Price to Sales (P/S)
since 2005
Calculation
Vertex Pharmaceuticals Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | 10.40 | = | 491.47 | ÷ | 47.24 | 47.24 | = | 12,001,300 | ÷ | 254,034,190 | |
| Feb 13, 2025 | 10.78 | = | 462.58 | ÷ | 42.91 | 42.91 | = | 11,020,100 | ÷ | 256,789,869 | |
| Feb 15, 2024 | 11.16 | = | 426.29 | ÷ | 38.21 | 38.21 | = | 9,869,200 | ÷ | 258,307,816 | |
| Feb 10, 2023 | 8.56 | = | 297.40 | ÷ | 34.74 | 34.74 | = | 8,930,700 | ÷ | 257,091,441 | |
| Feb 9, 2022 | 8.21 | = | 244.24 | ÷ | 29.75 | 29.75 | = | 7,574,400 | ÷ | 254,576,691 | |
| Feb 11, 2021 | 8.82 | = | 210.50 | ÷ | 23.87 | 23.87 | = | 6,205,683 | ÷ | 259,960,062 | |
| Feb 13, 2020 | 14.95 | = | 240.09 | ÷ | 16.06 | 16.06 | = | 4,162,821 | ÷ | 259,268,593 | |
| Feb 13, 2019 | 15.54 | = | 185.25 | ÷ | 11.92 | 11.92 | = | 3,047,597 | ÷ | 255,656,889 | |
| Feb 15, 2018 | 16.42 | = | 160.94 | ÷ | 9.80 | 9.80 | = | 2,488,652 | ÷ | 253,891,984 | |
| Feb 23, 2017 | 12.51 | = | 85.73 | ÷ | 6.85 | 6.85 | = | 1,702,177 | ÷ | 248,438,127 | |
| Feb 16, 2016 | 20.38 | = | 85.37 | ÷ | 4.19 | 4.19 | = | 1,032,336 | ÷ | 246,391,955 | |
| Feb 13, 2015 | 47.41 | = | 113.66 | ÷ | 2.40 | 2.40 | = | 580,415 | ÷ | 242,088,884 | |
| Feb 11, 2014 | 16.53 | = | 84.98 | ÷ | 5.14 | 5.14 | = | 1,211,975 | ÷ | 235,771,942 | |
| Mar 1, 2013 | 6.60 | = | 46.17 | ÷ | 7.00 | 7.00 | = | 1,527,042 | ÷ | 218,188,628 | |
| Feb 22, 2012 | 5.61 | = | 37.60 | ÷ | 6.71 | 6.71 | = | 1,410,626 | ÷ | 210,335,993 | |
| Feb 17, 2011 | 56.82 | = | 39.85 | ÷ | 0.70 | 0.70 | = | 143,370 | ÷ | 204,412,712 | |
| Feb 19, 2010 | 80.12 | = | 40.70 | ÷ | 0.51 | 0.51 | = | 101,889 | ÷ | 200,576,408 | |
| Feb 17, 2009 | 28.70 | = | 33.10 | ÷ | 1.15 | 1.15 | = | 175,504 | ÷ | 152,189,782 | |
| Feb 11, 2008 | 12.17 | = | 18.21 | ÷ | 1.50 | 1.50 | = | 199,012 | ÷ | 132,964,533 | |
| Mar 1, 2007 | 17.58 | = | 30.03 | ÷ | 1.71 | 1.71 | = | 216,356 | ÷ | 126,650,456 | |
| Mar 16, 2006 | 26.93 | = | 39.49 | ÷ | 1.47 | 1.47 | = | 160,890 | ÷ | 109,734,852 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
The price-to-sales (P/S) ratio exhibited considerable fluctuation between 2006 and 2026. Initial values were relatively high, followed by a period of decline, a subsequent surge, and eventual stabilization within a narrower range. A detailed examination reveals distinct phases in the ratio’s behavior.
- Early Volatility (2006-2009)
- From 2006 to 2009, the P/S ratio demonstrated significant volatility. It began at 26.93, decreased to 17.58, then further to 12.17, before rising sharply to 28.70. This period suggests changing investor expectations or market conditions impacting the valuation relative to sales.
- Peak and Subsequent Decline (2010-2016)
- The ratio peaked at 80.12 in 2010, representing a substantial increase. Following this peak, a pronounced downward trend was observed, decreasing to 20.38 by 2016. This decline coincided with fluctuations in sales per share, indicating a potential disconnect between price appreciation and revenue generation during this timeframe.
- Stabilization and Recent Trends (2017-2026)
- From 2017 onwards, the P/S ratio entered a period of relative stabilization, fluctuating between approximately 8 and 16. While some variation existed, the magnitude of change was considerably less than in previous periods. The ratio increased from 16.42 in 2017 to 11.16 in 2024, and then to 10.40 in 2026. This suggests a more mature valuation pattern, potentially reflecting increased confidence in the company’s revenue generation capabilities or a shift in investor sentiment.
The observed trends in the P/S ratio suggest a dynamic valuation history. The initial volatility, followed by a peak and subsequent decline, indicates a period of significant adjustment. The more recent stabilization suggests a more consistent valuation approach, although continued monitoring is warranted to assess long-term trends and potential shifts in market perception.
- Relationship to Sales per Share
- The P/S ratio’s movements appear correlated with changes in sales per share. Periods of declining P/S often coincided with lower sales per share, and vice versa. However, the relationship is not always direct, suggesting other factors, such as overall market conditions and investor sentiment, also play a role in determining the ratio.
Overall, the P/S ratio has demonstrated a complex pattern over the analyzed period, evolving from high volatility to a more stable range. The observed trends provide insights into the company’s valuation history and the factors influencing investor perception.
AI Ask an analyst for more
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | 10.40 | 6.50 | 5.66 | 2.53 | 6.02 | 15.03 | 6.34 | 6.16 | 4.71 | 2.46 | 5.71 | 4.34 |
| Feb 13, 2025 | 10.78 | 6.04 | 4.88 | 2.36 | 6.23 | 18.25 | 4.98 | 4.26 | 3.60 | 2.32 | 5.52 | 4.73 |
| Feb 15, 2024 | 11.16 | 5.72 | 5.78 | 2.19 | 7.76 | 20.77 | 3.40 | 4.43 | 5.43 | 2.61 | 7.84 | 4.99 |
| Feb 10, 2023 | 8.56 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 3.86 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 |
| Feb 9, 2022 | 8.21 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 2.85 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 |
| Feb 11, 2021 | 8.82 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 3.24 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 |
| Feb 13, 2020 | 14.95 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.00 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 |
| Feb 13, 2019 | 15.54 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 3.84 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 |
| Feb 15, 2018 | 16.42 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.10 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 |
| Feb 23, 2017 | 12.51 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 3.08 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 |
| Feb 16, 2016 | 20.38 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 3.80 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 |
| Feb 13, 2015 | 47.41 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 6.36 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 |
| Feb 11, 2014 | 16.53 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 11.95 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 |
| Mar 1, 2013 | 6.60 | 3.30 | 4.09 | 3.40 | 2.32 | 2.71 | 6.95 | 3.17 | 2.73 | 3.34 | 11.66 | 2.12 |
| Feb 22, 2012 | 5.61 | — | 3.52 | 2.63 | 2.28 | 1.87 | 4.22 | 2.75 | 2.43 | 2.37 | 20.90 | 1.77 |
| Feb 17, 2011 | 56.82 | — | 3.32 | 2.23 | 2.48 | 1.73 | 4.19 | 2.65 | 2.18 | 2.27 | 7.38 | 2.00 |
| Feb 19, 2010 | 80.12 | — | 3.88 | 2.27 | 2.16 | 1.82 | 6.64 | 2.82 | 4.23 | 2.83 | 5.74 | 1.98 |
| Feb 17, 2009 | 28.70 | — | 3.44 | 1.96 | 1.30 | 1.66 | 8.03 | 2.37 | 2.14 | 1.72 | 5.17 | 1.44 |
| Feb 11, 2008 | 12.17 | — | 3.46 | 2.30 | 2.16 | 3.05 | 10.90 | 2.95 | 4.04 | 3.11 | 11.94 | 2.40 |
| Mar 1, 2007 | 17.58 | — | 5.41 | 3.07 | 2.30 | 3.80 | 12.67 | 3.53 | 4.23 | 3.67 | 19.70 | 5.05 |
| Mar 16, 2006 | 26.93 | — | 7.24 | 2.34 | 2.40 | 4.31 | 15.36 | 3.49 | 3.50 | 3.77 | 14.06 | 2.15 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2026 | 10.40 | 6.24 |
| Feb 13, 2025 | 10.78 | 5.55 |
| Feb 15, 2024 | 11.16 | 5.89 |
| Feb 10, 2023 | 8.56 | 4.56 |
| Feb 9, 2022 | 8.21 | 4.50 |
| Feb 11, 2021 | 8.82 | 4.90 |
| Feb 13, 2020 | 14.95 | 4.88 |
| Feb 13, 2019 | 15.54 | 4.54 |
| Feb 15, 2018 | 16.42 | 4.60 |
| Feb 23, 2017 | 12.51 | 4.29 |
| Feb 16, 2016 | 20.38 | 4.10 |
| Feb 13, 2015 | 47.41 | 4.54 |
| Feb 11, 2014 | 16.53 | 4.30 |
| Mar 1, 2013 | 6.60 | 3.25 |
| Feb 22, 2012 | 5.61 | 2.58 |
| Feb 17, 2011 | 56.82 | 2.44 |
| Feb 19, 2010 | 80.12 | 3.00 |
| Feb 17, 2009 | 28.70 | 2.22 |
| Feb 11, 2008 | 12.17 | 3.19 |
| Mar 1, 2007 | 17.58 | 3.88 |
| Mar 16, 2006 | 26.93 | 3.84 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2026 | 10.40 | 3.34 |
| Feb 13, 2025 | 10.78 | 3.36 |
| Feb 15, 2024 | 11.16 | 3.52 |
| Feb 10, 2023 | 8.56 | 51,413.66 |
| Feb 9, 2022 | 8.21 | 3.28 |
| Feb 11, 2021 | 8.82 | 3.31 |
| Feb 13, 2020 | 14.95 | 3.21 |
| Feb 13, 2019 | 15.54 | 3.07 |
| Feb 15, 2018 | 16.42 | 3.06 |
| Feb 23, 2017 | 12.51 | 2.80 |
| Feb 16, 2016 | 20.38 | 2.72 |
| Feb 13, 2015 | 47.41 | 3.08 |
| Feb 11, 2014 | 16.53 | 2.81 |
| Mar 1, 2013 | 6.60 | 2.20 |
| Feb 22, 2012 | 5.61 | 1.90 |
| Feb 17, 2011 | 56.82 | 1.80 |
| Feb 19, 2010 | 80.12 | 2.08 |
| Feb 17, 2009 | 28.70 | 1.70 |
| Feb 11, 2008 | 12.17 | 2.42 |
| Mar 1, 2007 | 17.58 | 2.85 |
| Mar 16, 2006 | 26.93 | 3.17 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).